By Michael Susin
NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment.
In premarket trading ADRs were up $2.44 to $4.98. However, ADRs are down more than 80% on a 52-week basis.
The U.K. company said final data from the study of its asset NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma showed a prolonged progression free survival, a positive disease control rate and a favorable safety profile.
The company said that nine of the 12 patients achieved a disease control, including a patient who achieved a 55% reduction in tumor volume. Seven of them had a progression free survival time of greater than five months, which is highly atypical in this patient population, the company added.
"Outcomes in this patient population are very poor, with median progression free survival of two to three months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression free survival of more than five months," Chief Executive Hugh Griffith said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 16, 2024 06:18 ET (10:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。